• Insilico Medicine posted revenue of US$106.3 million, up 287.2% year over year.
• Net profit was US$35.5 million, returning to profit from a net loss of US$19.2 million.
• Non-IFRS adjusted profit reached US$51.23 million, swinging from an adjusted loss of US$15.41 million.
• Drug discovery and pipeline development revenue climbed 331.3% to US$103.1 million, driven mainly by upfront payments.
• Phase III trial in China started for ISM001-055 in IPF; 2026 deals totaled about US$7.3 billion in contract value.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insilico Medicine Cayman Topco published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260826-12299888), on August 26, 2026, and is solely responsible for the information contained therein.